U.S. Gene Therapy Market Size & Outlook, 2023-2030
The gene therapy market in the United States is expected to reach a projected revenue of US$ 18,484.0 million by 2030. A compound annual growth rate of 18.8% is expected of the United States gene therapy market from 2024 to 2030.
The U.S. gene therapy market generated a revenue of USD 5,533.7 million in 2023 and is expected to reach USD 18,484.0 million by 2030.
The U.S. market is expected to grow at a CAGR of 18.8% from 2024 to 2030.
In terms of segment, other vector type was the largest revenue generating vector type in 2023.
AAV is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
Market revenue in 2023
USD 5,533.7 million
Market revenue in 2030
USD 18,484.0 million
Growth rate
18.8% (CAGR from 2024 to 2030)
Largest segment
Other vector type
Fastest growing segment
AAV
Historical data
2018 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Lentivirus, AAV, RetroVirus & gamma RetroVirus, Modified Herpes Simplex Virus, Other Vector Type
Key market players worldwide
Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc
Other key industry trends
In terms of revenue, U.S. accounted for 64.5% of the global gene therapy market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In North America, U.S. gene therapy market is projected to lead the regional market in terms of revenue in 2030.
U.S. is the fastest growing regional market in North America and is projected to reach USD 18,484.0 million by 2030.
The U.S. is the largest market for clinical trials related to gene therapy, as around 50% of all clinical trials in the world are conducted in the country. As of March 2023, more than 2,500 clinical studies are under investigation in the U.S. alone.
A large number of gene therapy trials focus on finding feasible treatment options for cancer, closely followed by genetic diseases and neurological disorders.
The local presence of several large companies and small startups—working on the development of gene therapies—and partnerships & mergers between them are anticipated to boost the market.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Other Vector Type was the largest segment with a revenue share of 47.62% in 2023.
Horizon Databook has segmented the U.S. gene therapy market based on lentivirus, aav, retrovirus & gamma retrovirus, modified herpes simplex virus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for clinical trials related to gene therapy, as around 50% of all clinical trials in the world are conducted in the country. As of March 2023, more than 2,500 clinical studies are under investigation in the U.S. alone.
A large number of gene therapy trials focus on finding feasible treatment options for cancer, closely followed by genetic diseases and neurological disorders.
The local presence of several large companies and small startups—working on the development of gene therapies—and partnerships & mergers between them are anticipated to boost the market.
U.S. Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
Lentivirus
AAV
RetroVirus & gamma RetroVirus
Modified Herpes Simplex Virus
Adenovirus
Non-viral Plasmid Vector
Other Vector Type
U.S. Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Large B-cell Lymphoma
ADA-SCID
Melanoma (lesions)
Beta-Thalassemia Major/SCD
Head & Neck Squamous Cell Carcinoma
Peripheral arterial disease
Spinal Muscular Atrophy (SMA)
Others
Reasons to subscribe to Gene Therapy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.